Compare Air Products & Chemicals, Inc. (APD) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Crispr Therapeutics AG — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.88B), while Crispr Therapeutics AG trades at $54.08 (market cap $5.23B). The key difference: Air Products & Chemicals, Inc. is far larger — about 13.2× Crispr Therapeutics AG's market cap, and Air Products & Chemicals, Inc. pays a 2.34% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| APD | CRSP | |
|---|---|---|
Market Cap | $68.88B | $5.23B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $76.78 |
52-Week Low | $230.42 | $44.34 |
Enterprise Value | $86.06B | $3.65B |
Dividend Yield | 2.34% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
